Seven-year follow-up data on over 1400 patients show radium-223's long-term safety, with a low 2% secondary malignancy rate, reflecting real-world use.
Fred Saad, MD, FRCS
Fred Saad, MD, FRCS, is the Professor and Chairman of Urology and Director of Genitourinary Oncology at the University of Montreal Hospital Center.
Articles by Fred Saad, MD, FRCS
Fred Saad, MD, FRSC, discusses the findings of a biomarker analysis of the PROpel trial in patients with metastatic castration-resistant prostate cancer.
Fred Saad, MD, FRSC, discusses the key biomarkers looked at in an analysis of the phase 3 PROpel trial analyzing olaparib plus abiraterone to treat patients with metastatic castration resistant prostate cancer.
Fred Saad, MD, FRCS, University of Montreal, discusses the benefit of radium-223 for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).
Latest Updated Articles
Dr. Saad Discusses the Benefit of Radium-223 in Patients with mCRPCPublished: September 25th 2015 | Updated: